TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29410163

Group type: EXPERIMENTAL
Intervention: Observation in the ED or hospital for > 12 to < 24 h, followed by outpatient management with FDA-approved therapeutic anticoagulation.
Number of subjects: 200
Study: 29410304

Group type: EXPERIMENTAL
Intervention: POEM
Number of subjects: 143
Study: 29410330

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 2
Study: 29410385

Group type: EXPERIMENTAL
Intervention: PENFS treatment group (10 subjects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard therapy control group (10 subjects)
Number of subjects: 20
Study: 29410480

Group type: EXPERIMENTAL
Intervention: Weight history trajectories (recently overweight, always overweight, steady-gain-obese)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Time spent being overweight and current weight
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Concern about child weight
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Concern for child weight and mothers' body guilt
Number of subjects: 221
Study: 29410786

Group type: EXPERIMENTAL
Intervention: Tailored counseling letter intervention at month 1, 3, and 4
Number of subjects: 175

Group type: COMPARATOR
Intervention: Repeated assessments of PA and ST
Number of subjects: 175
Study: 29410955

Group type: EXPERIMENTAL
Intervention: 30g of prebiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29411318

Group type: EXPERIMENTAL
Intervention: Infliximab biosimilars
Number of subjects: 0

Group type: COMPARATOR
Intervention: Substitution policies for biosimilars
Number of subjects: 0
Study: 29411338

Group type: EXPERIMENTAL
Intervention: Infusion safety intervention bundle
Number of subjects: 840
Study: 29412457

Group type: EXPERIMENTAL
Intervention: CRIS classifier
Number of subjects: 543

Group type: COMPARATOR
Intervention: CMS classification
Number of subjects: 543
Study: 29412688

Group type: EXPERIMENTAL
Intervention: Long-Acting β-Agonist/Inhaled Corticosteroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29412784

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) added to radiotherapy plus temozolomide (RT+TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy plus temozolomide (RT+TMZ)
Number of subjects: 0
Study: 29413039

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29413142

Group type: EXPERIMENTAL
Intervention: Active attention bias modification (ABM) training (n = 40)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Active attention bias modification (ABM) training (n = 15)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo protocol (n = 41)
Number of subjects: 84
Study: 29413360

Group type: EXPERIMENTAL
Intervention: Increased n-3 EPA+DHA with low n-6 linoleic acid (H3 L6)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Increased n-3 EPA+DHA with usual US dietary intake of n-6 linoleic acid (H3 H6)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual US dietary content of n-3 and n-6 fatty acids (L3 H6)
Number of subjects: 153
Study: 29413510

Group type: EXPERIMENTAL
Intervention: Morning symptoms
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Increased symptoms
Number of subjects: 734
Study: 29413684

Group type: EXPERIMENTAL
Intervention: HER family inhibitors (trastuzumab, lapatinib, afatinib)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (lapatinib or afatinib)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Other molecularly targeted agents (mTOR, PI3K, NOTCH inhibitors, chemotherapy)
Number of subjects: 31
Study: 29414920

Group type: EXPERIMENTAL
Intervention: Successful Left Atrial Appendage Closure (LAAC)
Number of subjects: 44
Study: 29414995

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zileuton plus placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All treatment cohorts
Number of subjects: 24
Study: 29415190

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily alone (days 1-4)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily with isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Isoniazid and rifapentine (days 5-19)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rifapentine and 25-desacetyl rifapentine (day 19)
Number of subjects: 4
Study: 29415580

Group type: EXPERIMENTAL
Intervention: 20:1 cafedrine/theodrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 0
Study: 29415760

Group type: EXPERIMENTAL
Intervention: Mobile Critical Care Recovery Program (m-CCRP)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Attention control (printed material and telephone reminders)
Number of subjects: 620
Study: 29415831

Group type: EXPERIMENTAL
Intervention: 5 min steady state (SS) criterion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 3 min steady state (SS) criterion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Comparison of SS criteria
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 3 min SS vs 5 min SS
Number of subjects: 68
Study: 29415853

Group type: EXPERIMENTAL
Intervention: Fentanyl exposure (positive toxicology test)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Heroin use
Number of subjects: 231

Group type: COMPARATOR
Intervention: Non-heroin opioids use
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Belief about fentanyl exposure
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Expectation of negative test results
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Never exposed to fentanyl
Number of subjects: 231
Study: 29415874

Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE) imaging using the Cystoflex UHD-R probe in bladder study (60 patients)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE) imaging during ureterorenoscopy in upper urinary tract study (25 patients)
Number of subjects: 85
Study: 29416368

Group type: EXPERIMENTAL
Intervention: Nutriage day cream (morning application)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nutriage night cream (evening application)
Number of subjects: 22
Study: 29416652

Group type: EXPERIMENTAL
Intervention: Rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4, along with HD-MTX 3.5g/m2, vincristine, procarbazine, cytarabine, and dexamethasone taper.
Number of subjects: 26
Study: 29416870

Group type: EXPERIMENTAL
Intervention: Couple-based mind-body (CBMB) intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 75
Study: 29416871

Group type: EXPERIMENTAL
Intervention: Anesthesiology Control Tower (telemedicine-based intra-operative clinical support system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase I testing (think-aloud protocol analyses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase II testing (qualitative and quantitative in situ usability and feasibility analysis)
Number of subjects: 0
Study: 29416872

Group type: EXPERIMENTAL
Intervention: Risk prompts for falls, dehydration, and pulmonary aspiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk prompts
Number of subjects: 0
Study: 29416986

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m²) in combination with doxorubicin and cyclophosphamide (CAP regimen)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cisplatin in association with doxorubicin and cyclophosphamide
Number of subjects: 41
Study: 29417092

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 10 hours of treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (various sedation methods)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 30
Study: 29417310

Group type: EXPERIMENTAL
Intervention: First-void urine samples
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cervical samples
Number of subjects: 110
Study: 29417430

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily with background MTX
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily with background GC
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Tofacitinib without MTX, initiated MTX
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Tofacitinib without GC, initiated GC
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Tofacitinib with MTX/GC discontinuation
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Tofacitinib with MTX initiation
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Tofacitinib with GC initiation
Number of subjects: 3030
Study: 29419390

Group type: EXPERIMENTAL
Intervention: Higher levels of ApoA1
Number of subjects: 14884

Group type: COMPARATOR
Intervention: Composite ischemic outcome (ischemic stroke, systemic embolism, myocardial infarction, and cardiovascular death)
Number of subjects: 14884
Study: 29419425

Group type: EXPERIMENTAL
Intervention: Plerixafor (dose escalation)
Number of subjects: 0
Study: 29419434

Group type: EXPERIMENTAL
Intervention: Deep sequencing and flow cytometric characterization
Number of subjects: 0
Study: 29419698

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) based approach for the detection of relevant infecting organisms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard (culture-based) microbiological diagnostics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NGS-based approach
Number of subjects: 0
Study: 29420116

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV7)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immunocompetent controls
Number of subjects: 24
Study: 29420218

Group type: EXPERIMENTAL
Intervention: Low neighborhood socioeconomic status (SES)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Middle neighborhood socioeconomic status (SES)
Number of subjects: 525

Group type: COMPARATOR
Intervention: High neighborhood socioeconomic status (SES)
Number of subjects: 525
Study: 29420335

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 0
Study: 29420341

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Trial cohort (patients with exclusion criteria for enrollment into current interventional trials)
Number of subjects: 778
Study: 29420395

Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 29420467

Group type: EXPERIMENTAL
Intervention: Neratinib (pan-HER kinase inhibitor)
Number of subjects: 0
Study: 29420708

Group type: EXPERIMENTAL
Intervention: S4 cells in females
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: S7 cells
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: S4 cells
Number of subjects: 100
Study: 29420795

Group type: EXPERIMENTAL
Intervention: Opioid therapy in younger patients (<50 years)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Opioid therapy in older patients (50-64 years)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Opioid therapy in younger and older patients
Number of subjects: 419
Study: 29421016

Group type: EXPERIMENTAL
Intervention: Deferred invasive strategy
Number of subjects: 696

Group type: COMPARATOR
Intervention: Early invasive strategy
Number of subjects: 696
Study: 29421314

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study: 29421336

Group type: EXPERIMENTAL
Intervention: Pre-intervention high-fat food cravings
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pre-intervention fast-food cravings
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post- vs. pre-intervention change in sweet cravings
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post- vs. pre-intervention change in fast food cravings
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Changes in cravings for starchy food
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Changes in overall food cravings
Number of subjects: 32
Study: 29421959

Group type: EXPERIMENTAL
Intervention: Angioseal® closure device with early ambulation at 20 min after deployment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional care with prolonged bed rest of 2-3 hours
Number of subjects: 29
Study: 29421974

Group type: EXPERIMENTAL
Intervention: Stanford Leisure-Time Activity Categorical Item (L-Cat)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Adapted Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: L-Cat and adapted GLTEQ measures
Number of subjects: 301
Study: 29422014

Group type: EXPERIMENTAL
Intervention: Tailored strategy to improve guideline adherence, including a risk assessment checklist, care bundle, and time-out procedure.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient empowerment tools including a patient passport and a website with patient information.
Number of subjects: 0
Study: 29422039

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 12
Study: 29422070

Group type: EXPERIMENTAL
Intervention: Copeptin levels
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Urea values
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low urine osmolality
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Copeptin and urea
Number of subjects: 92
Study: 29422454

Group type: EXPERIMENTAL
Intervention: Do CHANGE service with Do Something Different (DSD) program to assist in changing unhealthy habits.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Do CHANGE service with monitoring devices (Fitbit, Beddit, COOKiT, FLUiT) integrated in one application.
Number of subjects: 250
Study: 29422724

Group type: EXPERIMENTAL
Intervention: Continuous subglottic suctioning (CSSS) at -20 mmHg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intermittent subglottic suctioning (ISSS) at -100 mmHg
Number of subjects: 73
Study: 29422881

Group type: EXPERIMENTAL
Intervention: Wrist-worn activity tracking device providing multimodal feedback on daily arm use for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Identical device providing no feedback
Number of subjects: 62
Study: 29423219

Group type: EXPERIMENTAL
Intervention: Protein supplementation (Cubitan, 20g protein taken orally 3 times a day for 6 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (zero-protein ampule with identical instructions)
Number of subjects: 160
Study: 29423259

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 30
Study: 29423515

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1) given intravenously every 3 weeks until unacceptable toxic effects, protocol nonadherence, or loss of clinical benefit.
Number of subjects: 95
Study: 29424248

Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29424480

Group type: EXPERIMENTAL
Intervention: Clinical and biomarker strategy for predicting incident HF
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Model without biomarkers
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Model with biomarkers
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Risk score for predicting incident HF
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Internal validation of the model
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers
Number of subjects: 991
Study: 29424677

Group type: EXPERIMENTAL
Intervention: Sublaminar band placement at the upper instrumented vertebra (UIV) plus 1 level (UIV+1) during long-segment thoracolumbar arthrodesis surgery.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sublaminar band placement at the UIV+1 during long-segment thoracolumbar arthrodesis surgery.
Number of subjects: 40
Study: 29424775

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen
Number of subjects: 27
Study: 29425270

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI and resting-state functional MRI
Number of subjects: 0
Study: 29426039

Group type: EXPERIMENTAL
Intervention: MRproANP
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: C-terminal proendothelin 1
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Midregional-proadrenomedullin
Number of subjects: 689
Study: 29426345

Group type: EXPERIMENTAL
Intervention: Community engagement strategy involving community knowledge brokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29426361

Group type: EXPERIMENTAL
Intervention: Systematic follow-up by nurses with three home visits over a period of 1 month.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care guidelines of the health services (control group).
Number of subjects: 48
Study: 29426380

Group type: EXPERIMENTAL
Intervention: Occupation-Based Coaching via telehealth
Number of subjects: 18
Study: 29426382

Group type: EXPERIMENTAL
Intervention: 1-wk activity program
Number of subjects: 0
Study: 29426386

Group type: EXPERIMENTAL
Intervention: Mirror therapy and task-oriented training
Number of subjects: 4
Study: 29426394

Group type: EXPERIMENTAL
Intervention: Manualized occupation-based diabetes management intervention
Number of subjects: 8
Study: 29428177

Group type: EXPERIMENTAL
Intervention: Caregiver demographic factors (self-reported black vs. white race and high school or less education vs. college or more)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Caregiver's inability to get an immunization appointment as soon as needed
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Adolescent's type of insurance
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Caregiver or adolescent attitudes and beliefs about on-schedule HPV vaccination or HPV vaccine safety
Number of subjects: 868
Study: 29428178

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 3-dose regimen of qHPV vaccine
Number of subjects: 468
Study: 29428183

Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment (coverage rate of 84%)
Number of subjects: 16092

Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment
Number of subjects: 16092
Study: 29428438

Group type: EXPERIMENTAL
Intervention: Malnutrition (BMI <5% for age or weight-for-length <5% for <2 years)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Obesity (BMI >95% for age or weight-for-length >95% for <2 years)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Normal bodyweight (NB)
Number of subjects: 904
Study: 29428572

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 6623
Study: 29428788

Group type: EXPERIMENTAL
Intervention: N.I.R. H.E.G. neurofeedback training
Number of subjects: 6
Study: 29428999

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 62
Study: 29429017

Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM) plus digital breast tomosynthesis (DBT)
Number of subjects: 24301

Group type: COMPARATOR
Intervention: Full-field digital mammography (FFDM) alone
Number of subjects: 24301
Study: 29429807

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 41385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41385
Study: 29429815

Group type: EXPERIMENTAL
Intervention: JE-VC (2nd booster dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: JE-MB (1st booster dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: JE-VC (1st booster dose)
Number of subjects: 0
Study: 29430250

Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (5 outpatient sessions)
Number of subjects: 710
Study: 29430278

Group type: EXPERIMENTAL
Intervention: H-AVA group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-AVA group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVA-B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVA-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVA-C
Number of subjects: 0
Study: 29430306

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 6
Study: 29430747

Group type: EXPERIMENTAL
Intervention: Global left atrial strain (LA-GS) measurement
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Symptom severity assessment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Echocardiographic and hemodynamic parameters measurement
Number of subjects: 86
Study: 29431103

Group type: EXPERIMENTAL
Intervention: N-terminal-pro-b-type natriuretic peptide (NT-proBNP) levels at baseline
Number of subjects: 686
Study: 29431128

Group type: EXPERIMENTAL
Intervention: Light-intensity PA
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity PA
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines
Number of subjects: 425
Study: 29431735

Group type: EXPERIMENTAL
Intervention: Vhl-deficient osteoblasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with dichloroacetate (DCA)
Number of subjects: 0
Study: 29431878

Group type: EXPERIMENTAL
Intervention: Infarct volume on diffusion-weighted imaging on day 0
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Infarct volume on FLAIR on day 6
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: NIH Stroke Scale score on admission/discharge
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lesion volumes on FLAIR on day 6
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dysphagia
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 61
Study: 29432037

Group type: EXPERIMENTAL
Intervention: Cognitive neuroscience-based interventions in school settings
Number of subjects: 0